视网膜中央静脉阻塞的危险因素研究

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨视网膜中央静脉阻塞的危险因素。方法回顾性分析2013年1月～2016年12月本院的258例门诊及住院患者的临床资料，其中视网膜中央静脉阻塞组132例（研究组），非视网膜中央静脉阻塞患者126例（对照组）。比较两组的血糖、血脂四项（TG、TC、HDL-C，LDL-C）、血小板计数、血纤维蛋白原、血D-二聚体水平。结果单因素分析显示，两组的高血压、糖尿病、吸烟者占比及D-二聚体水平比较，差异有统计学意义（P＜0.05）。校正年龄、吸烟等因素后，Logistic逐步回归分析显示高血压、糖尿病史及D-二聚体水平是视网膜中央静脉阻塞的独立危险因素（D-二聚体：OR=1.31，95%CI：1.028～1.894，P=0.041；高血压病史：OR=1.24，95%CI：1.094～1.672，P=0.039；糖尿病史：OR=1.37，95%CI：1.128～1.933，P=0.046）。缺血型与非缺血型视网膜中央静脉阻塞患者的D-二聚体水平比较，差异有统计学意义（P＜0.05）。结论D-二聚体增高、高血压及糖尿病是视网膜中央静脉阻塞发生的独立危险因素，可作为视网膜中央静脉阻塞预测的指标。D-二聚体水平增高可能与缺血型视网膜中央静脉阻塞相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	樊利敏
	杨波
	计青
	李乃洋

关键词 ：视网膜中央静脉阻塞, D-二聚体, 危险因素

Abstract：ObjectiveTo investigate the risk factors of central retinal vein occlusion.MethodsThe clinical data of 258 cases of outpatients and inpatients in our hospital from January 2013 to December 2016 were retrospectively analyzed in this study.Among them,there were 132 cases of central retinal vein occlusion(the study group),and 126 cases was non central retinal vein occlusion(the control group).The level of blood glucose,blood lipid(triglyceride,cholesterol,high density lipoprotein,low density lipoprotein),platelet count,fibrinogen and blood D-dimer in the two groups was compared.ResultsUnivariate analysis showed that there was significant difference in the level of hypertension,diabetes,smoking and D-dimer between the two groups(P＜0.05).After adjusting for age,smoking and other factors,Logistic regression analysis showed that the hypertension,diabetes and D-dimer levels were independent risk factors for central retinal vein occlusion(D-dimer:OR=1.31,95%CI:1.028-1.894,P=0.041;hypertension:OR=1.24,95%CI:1.094-1.672,P=0.039;diabetes:OR=1.37, 95%CI:1.128-1.933,P=0.046).The level of D-dimer was significantly different between ischemic and non-ischemic central retinal vein occlusion(P＜0.05).ConclusionThe increase of D-dimer,hypertension and diabetes are independent risks factor for central retinal vein occlusion.D-dimer,hypertension and diabetes may be the predictor of central retinal vein occlusion.The level of D-dimer may be related to ischemic central retinal vein occlusion.

Key words： Central retinal vein occlusion D-dimer Risk factor

基金资助:广东省深圳市宝安区科技计划项目（2013165）

引用本文:

樊利敏；杨波；计青；李乃洋. 视网膜中央静脉阻塞的危险因素研究[J]. 中国当代医药, 2017, 24(19): 7-10.
FAN Li-min；YANG Bo；JI Qing；LI Nai-yang. Risk factors study of central retinal vein occlusion. 中国当代医药, 2017, 24(19): 7-10.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I19/7

[5]	Bremond-Gignac D.Investigational drugs for retinal vein occlusion[J].Expert Opin Investig Drugs，2016，25（7）：841-850.
[13]	Sivalingam A，Brown GC，Magargal LE.The ocular ischemic syndromeⅡ.Mortality and systemic morbidity[J].Int ophthalmol，1989，13：187-191.
[17]	Sathe PM，Patwa UD.D-Dimer in acute care[J].Int J Crit Illn Inj Sci，2014，4（3）：229-232.
[1]	Karska-Basta I，Kubicka-Trzaska A，Pogrzebielski A，et al. A new insight into retinal vein occlusion pathogenesis[J]. Klin Oczna，2013，115（4）：269-274.
[2]	Lorenz K，Scheller Y，Bell K，et al.A prospective，randomised，placebo-controlled，double-masked，three-armed，multicentre phaseⅡ/Ⅲtrial for the study of a topical treatment of ischaemic central retinal vein occlusion to prevent neovascular glaucoma-the STRONG study：study protocol for a randomised controlled trial[J].Trials，2017，18（1）：128.
[3]	Wan H，Wu S，Yang Y，et al.Plasma fibrin D-dimer and the risk of left atrial thrombus：a systematic review and metaanalysis[J].PLoS One，2017，12（2）：e0172272.
[4]	Aghamirsalim M，Sorbi R，Naderian M，et al.Management of retinal vein occlusion，who is responsible[J].Acta Med Iran，2016，54（11）：731-736.
[6]	Chang YS，Weng SF，Chang C，et al.Risk of retinal vein occlusion following end-stage renal disease[J].Medicine（Baltimore），2016，95（16）：e3474.
[7]	Li M，Hu X，Huang J，et al.Impact of retinal vein occlusion on stroke incidence：a Meta-analysis[J].J Am Heart Assoc，2016，5（12）：e004703.
[8]	Woo SC，Lip GY，Lip PL.Associations of retinal artery occlusion and retinal vein occlusion to mortality，stroke，and myocardial infarction：a systematic review[J].Eye（Lond），2016，30（8）：1031-1038.
[9]	Napal JJ，Neila S，Pérez-Montes R，et al.The role of coagulation disorders in patients with retinal vein occlusion[J]. QJM，2016，109（2）：97-102.
[10]	Chapin J，Carlson K，Christos PJ，et al.Risk factors and treatment strategies in patients with retinal vascular occlusions[J].Clin Appl Thromb Hemost，2015，21（7）：672-677.
[11]	The Eye Disease Case-Control Study Group.Risk factors for central retinal vein occlusion[J].Arch Ophthalmol，1996，114（5）：545-554.
[12]	Hayreh SS，Zimmerman B，McCarthy MJ，et al.Systemic diseasesassociatedwithvarioustypesofretinalveinocclusion[J]. American journal of ophthalmology，2001，131（1）：61-77.
[14]	Russo PD，Damante G，Pasca S，et al.Thrombophilic mutations as risk factor for retinal vein occlusion：a case-control study[J].Clin Appl Thromb Hemost，2015，21（4）：373-377.
[15]	Folsom AR，Alonso A，George KM，et al.Prospective study of plasma D-dimer and incident venous thromboembolism：the atherosclerosis risk in communities（ARIC）study[J]. Thromb Res，2015，136（4）：781-785.
[16]	Soomro AY，Guerchicoff A，Nichols DJ，et al.The current role and future prospects of D-dimer biomarker[J].Eur Heart J Cardiovasc Pharmacother，2016，2（3）：175-184.